TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who received a prescription for a SGLT2 inhibitor or DPP-4 inhibitor on or after the date of the first dispensation of a SGLT2 inhibitor at each site and on or before June 30, 2018 (or latest date of data availability at each site)~Exclusion Criteria:~* Patients who received both a first prescription for a SGLT2 inhibitor and a DPP-4 inhibitor on the same date~* Patients with missing sex~* Patients aged less than 18 years at cohort entry date (\<19 years in Alberta and \<66 years in Ontario)~* Patients with less than 365 days of healthcare coverage prior to cohort entry date~* Patients with date inconsistencies or no follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors (Type: None): Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors (Type: None): Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amitriptyline to Prevent Headache After Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute mild TBI (Glasgow Coma Scale of 13-15 on emergency department evaluation, any period of loss of consciousness (LOC) \< than 30 minutes, alteration of consciousness or post-traumatic amnesia (not to exceed 24 hours)~* Ability to give consent~* Ages 18-60~* Access to a telephone~* Current headache (new headache or headache worse than prior to injury)~Exclusion Criteria:~* Does not speak English~* Diagnosed seizure disorder~* Myocardial infarction in prior 6 months~* Cardiac arrhythmia requiring medication treatment~* Prolonged Q-T interval on electrocardiogram~* Psychosis~* Intoxication on hospital admission sufficient enough to cloud the diagnosis of mild TBI~* Incarceration or homelessness~* Allergy to amitriptyline~* Current treatment with amitriptyline or other tricyclic antidepressant~* Currently taking any medication not recommended for use with amitriptyline due to the potential for Q-T interval prolongation. Examples of this include: Class I, I-A or II antiarrhythmics, TCA's, MAOI's, selected fluoroquinolones (gatifloxacin, moxifloxacin), selected antipsychotic medications (haloperidol, risperidone, quetiapine), selected antiretroviral medications, cisapride, chloroquine, chlorpromazine, prochlorperazine, promethazine, citalopram, fluoxetine, erythromycin, methadone~* History of glaucoma~* History of prostate disease or current urinary retention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Amitriptyline Immediate (Type: EXPERIMENTAL): The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
- Amitriptyline Delayed (Type: EXPERIMENTAL): The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet current DSM-5 criteria for an alcohol, stimulant, cannabis, or opioid use disorder.~* Are sufficiently stable for 4 weeks of outpatient treatment.~* Are willing to provide locator information.~* Are fluent in English and have a 4th grader or higher reading level~Exclusion Criteria:~* Meet DSM-5 criteria for a bipolar or schizophrenic disorder.~* Who have a legal case pending such that incarceration during the 4-week protocol is likely.~* Are physically dependent on alcohol, opioids or benzodiazepines or who report recent PCP use.~* Have a baseline Shipley estimated IQ less than 70~* Have 3 or more head injuries with loss of consciousness for over 30 minutes or lasting effects~* Have a history of chronic illness or neurological disorders (e.g., epilepsy or stroke) that would complicate evaluation of effects of cognitive training

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- TAU plus Cognitive Remediation Program (Type: EXPERIMENTAL): Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
- TAU plus Control Tasks (Type: PLACEBO_COMPARATOR): Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old ≤age≤65 years of age,male.~* Hemophilia A or B patients with inhibitors.~* Peak historical inhibitor titer ≥ 5 BU and a positive inhibitor test when enrolled.~* Establish proper venous access.~* Provide signed informed consent.~Exclusion Criteria:~* Have any coagulation disorder other than hemophilia A or B.~* Treat with prophylactic treatment of coagulation factor.~* Treat with anticoagulant within 7d of the time of study drug administration.~* Have an active, ongoing bleeding for which the patient is being treated, or treatment for a bleeding was stopped within 7d of the time of study drug administration.~* Have a history of arterial and/or venous thromboembolic events.~* Have platelet count \<100,000/mL.~* Severe liver or kidney disease.~* Accept major operation or blood transfusion within 1 month of the time of screening.~* HIV antibody positive.~* Have a known allergy to Blood product.~* Participate in other clinical research within 1 month of the time of study drug administration.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A single lowest dose of treatment group (Type: EXPERIMENTAL): None
- A single low dose of treatment group (Type: EXPERIMENTAL): None
- A single low-intermediate dose of treatment group (Type: EXPERIMENTAL): None
- A single intermediate dose of treatment group (Type: EXPERIMENTAL): None
- A single high dose of treatment group (Type: EXPERIMENTAL): None
- A single highest dose of treatment group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2~* Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction~* Leukocytes \>= 3,000/uL~* Absolute neutrophil count \>= 1,500/uL~* Platelets \>= 60,000/Ul~* Serum creatinine =\< 1.5 mg/dL~* Distant metastatic disease of peritoneum may be visualized on imaging:~  * Positive peritoneal cytology~ * Carcinomatosis on diagnostic laparoscopy or laparotomy~* Completion of preoperative systemic chemotherapy and preoperative laparoscopic HIPEC~Exclusion Criteria:~* Distant metastatic disease not limited to peritoneum: Solid organ metastases (liver, central nervous system, lung)~* Infections such as pneumonia or wound infections that would preclude protocol therapy~* Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence~* Subjects with unstable angina or New York Heart Association grade II or greater congestive heart failure~* Subjects deemed unable to comply with study and/or follow-up procedures~* Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (mitomycin, cisplatin) (Type: EXPERIMENTAL): Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older;~2. HSV-2 seropositive by Western Blot;~3. not receiving any drugs with known anti-HSV-2 activity for study duration;~4. history of primary genital herpes infection within past 6 months OR history of 4 or more HSV recurrences per year during the past year OR 4 or more recurrences per year prior to initiation of suppressive antiviral therapy;~5. able to comply with the study protocol;~6. women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;~7. women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;~8. in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;~9. planning to remain resident in the area of the study center for the duration of the study participation;~10. HIV seronegative.~Exclusion Criteria:~1. hypersensitivity to acyclovir or valacyclovir;~2. pregnant women;~3. HIV positive or other immunosuppressed state, including chronic steroid use. Intermittent nasal or topical steroids are acceptable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose (Type: ACTIVE_COMPARATOR): None
- High-dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males \& females, 18-77 years old inclusive, with type 2 diabetes and with inadequate glycemic control~* Drug naive or treated with anti-diabetic medication for \< 24 weeks since original diagnosis~* C-peptide ≥ 1.0 ng/mL~* Body Mass Index ≤ 45.0 kg/m~* Serum creatinine \< 1.50 mg/dL for men or \< 1.40 mg/dL for women~Exclusion Criteria:~* AST and/or ALT \>3.0 times the upper limit of normal (ULN)~* Serum total bilirubin \> 2.0 mg/dL~* Creatine kinase \> 3X the upper limit of normal (ULN)~* Symptoms of severely uncontrolled diabetes~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
- Arm 2 (Type: EXPERIMENTAL): Dapagliflozin (5 mg)
- Arm 3 (Type: ACTIVE_COMPARATOR): Metformin XR (500 mg up to 2000 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: D-serine Adjuvant Treatment for Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PD diagnosis~* ≥2 on UPDRS items 32,33~* receive treatment with L-dopa alone or in combination with other antiparkinsonian medications.~Exclusion Criteria:~* current or previous history of other neurological disorders~* unstable medical conditions~* renal pathology~* pregnant female patients excluded

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria TTE Main Study:~1. Subject 18 years of age and older.~2. Subject presents with a clinical condition characterized by neurological signs and symptoms that, in the opinion of the investigator, include embolic stroke or transient ischemic attack (TIA) in the differential diagnosis.~3. Scheduled for a transthoracic echocardiograph (TTE) study with agitated saline contrast (bubble study) per standard of care within ±30 days of informed consent.~4. Subject is able to successfully perform a Valsalva Maneuver (VM).~5. Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.~Exclusion Criteria TTE Main Study:~1. Subject has undergone a right to left shunt (RLS) or patent foramen ovale (PFO) closure.~2. Female who is pregnant or lactating at time of admission~3. Subjects who underwent partial or full craniotomy/craniectomy within the past 6 months.~4. Subjects who have a physical limitation preventing TCD headset placement~Inclusion Criteria TEE Sub-Study (after first 150 subjects in Main TTE study enrolled):~1. Subject 18 years of age and older.~2. Subject presents with a clinical condition characterized by neurological signs and symptoms that, in the opinion of the investigator, include embolic stroke or TIA in the differential diagnosis.~3. Scheduled for a transesophageal echocardiograph (TEE) study with agitated saline contrast (bubble study) per standard of care within ±30 days of informed consent.~4. Subject is able to successfully perform a Valsalva Maneuver (VM).~5. Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.~Exclusion Criteria TEE Sub-Study (after first 150 subjects in Main TTE study enrolled):~1. Subject has undergone a right to left shunt (RLS) or patent foramen ovale (PFO) closure.~2. Female who is pregnant or lactating at time of admission~3. Subjects who underwent partial or full craniotomy/craniectomy within the past 6 months.~4. Subjects who have a physical limitation preventing TCD headset placement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NeuralBot Investigational System/TTE Std of Care (Type: EXPERIMENTAL): Investigational Robotic Transcranial Doppler (TCD)/TTE Std of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Puregon® (recFSH)/Orgalutran® group:~  * Women with a pregnancy of \>= 16 weeks after Puregon® /Orgalutran® treatment for IVF or ICSI and ET of fresh embryos. Treatment is defined as having had at least one injection of Orgalutran®.~ * Women between 18 and 39 years of age (inclusive) at the day of hCG.~ * Women who are able and willing to sign informed consent.~Controls~* Infants (gestational age \>=16 weeks) of women pregnant after COH using a GnRH agonist in a long protocol for IVF or ICSI and ET of fresh embryos.~* Infants of women between 18 and 39 years of age (inclusive) at the day of hCG.~* The most recent 1000 infants delivered prior to January 1, 2001.~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Observational Cohort (Type: None): Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone/ganirelix followed by in vitro fertilization or intra cytoplasmatic sperm injection.
- Historical Controls (Type: None): Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone in a long protocol with a gonadotropin releasing hormone agonist followed by IVF or ICSI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recipients of matched related, matched unrelated, or mismatched stem cell transplantation~* At least 180 days since allogeneic stem cell transplantation procedure~* Patients must have steroid-refractory chronic GVHD, defined as having persistent signs and symptoms despite the use of prednisone~* Stable dose of corticosteroids for 4 weeks prior to enrollment~* Adequate bone marrow function: absolute neutrophil count (ANC) \> 500/mm; platelets \> 20,000 ul~* Adequate renal function: creatinine \< 3.0 mg/dl~* Adequate hepatic function: bilirubin \< 3.0 mg/dl; AST \< 90 IU~Exclusion Criteria:~* Prednisone requirement greater than 2 mg/kg/day or equivalent~* Known life-threatening sensitivity to rituximab or other anti-B cell antibody.~* Prior exposure to any new immunosuppressive medication in the preceding 4 weeks prior to enrollment.~* Active, uncontrolled infection~* Evidence of natural exposure to hepatitis B or C.~* Active malignant disease relapse~* Donor lymphocyte infusion within the preceding 100 days.~* Life expectancy of less than 3 months.~* Pregnancy or lactation~* Evidence of HIV seropositivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age ≥ 50 years~* Treatment naive AMD patients that are determined to be candidates for ranibizumab~* Visual acuity 20/40 to 20/320~Exclusion Criteria:~* Pregnancy~* Prior enrollment in the study~* Previous therapy for AMD or other retinal diseases which may be used in the treatment of AMD~* Any other condition that the investigator believes would pose a significant hazard to the subject if on-label ranibizumab were prescribed~* Any condition that would interfere with the ERG recording (such as media opacities including lens or corneal opacity)~* Concurrent eye disease in the study eye that could compromise visual acuity (such as diabetic retinopathy, advanced glaucoma)~* Any condition causing the patient to have a significant tremor that would interfere with the patient's ability to remain still during the ERG (such as Parkinson's disease)~* Participation in another simultaneous medical investigation or trial

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete